These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 31829737

  • 1. Approaches to improve drug tolerance and target tolerance in the assessment of neutralizing anti-drug antibodies.
    Wu B, Schnarr M, Devlin JL, Brown S, Yang TY.
    Bioanalysis; 2019 Nov; 11(22):2061-2074. PubMed ID: 31829737
    [Abstract] [Full Text] [Related]

  • 2. Assay development considerations to improve drug tolerance in direct competitive ligand binding neutralizing antibody assays, pretreatment strategies.
    Rathi A, Rinker S, Niu H, Carter C, Kumar S, Cowan K.
    J Immunol Methods; 2023 Jun; 517():113484. PubMed ID: 37116778
    [Abstract] [Full Text] [Related]

  • 3. Strategies to develop highly drug-tolerant cell-based neutralizing antibody assay: neutralizing antidrug antibodies extraction and drug depletion.
    Jiang Z, Kamerud J, Zhang M, Ruiz CC, Guadiz C, Fichtner A, Gorovits B.
    Bioanalysis; 2020 Sep; 12(18):1279-1293. PubMed ID: 32945693
    [Abstract] [Full Text] [Related]

  • 4. Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody.
    Xiang Y, Parng C, Olson K, Seletskaia E, Gorovits B, Jani D, Caiazzo T, Joyce A, Donley J.
    AAPS J; 2019 Mar 29; 21(3):46. PubMed ID: 30927117
    [Abstract] [Full Text] [Related]

  • 5. Highly drug/target-tolerant neutralizing antibody (NAb) assay development through target-based drug depletion and drug-based NAb extraction for an anti-EGFR therapeutic monoclonal antibody.
    Fu R, Xu J, Guo Q, Liu T, Su X, Xu M, Zhao X, Wang F, Ji L, Qian W, Hou S, Li J, Zhang D, Guo H.
    J Pharm Biomed Anal; 2024 Apr 15; 241():116006. PubMed ID: 38309099
    [Abstract] [Full Text] [Related]

  • 6. Comparison of cell-based and non-cell-based assay platforms for the detection of clinically relevant anti-drug neutralizing antibodies for immunogenicity assessment of therapeutic proteins.
    Hu J, Wala I, Han H, Nagatani J, Barger T, Civoli F, Kaliyaperumal A, Zhuang Y, Gupta S.
    J Immunol Methods; 2015 Apr 15; 419():1-8. PubMed ID: 25795420
    [Abstract] [Full Text] [Related]

  • 7. Bead-extraction and heat-dissociation (BEHD): A novel way to overcome drug and matrix interference in immunogenicity testing.
    Xu W, Sank M, Cummings J, Carl S, Juhel M, Gleason C, Dodge R, DeSilva BS, Kolaitis G, Pillutla R.
    J Immunol Methods; 2018 Nov 15; 462():34-41. PubMed ID: 30099014
    [Abstract] [Full Text] [Related]

  • 8. Approaches to Resolve False Reporting in Neutralizing Antibody Assays Caused by Reagent Leaching from Affinity Capture Elution Solid Phase.
    Xiang Y, Kamerud J, Donley J, Olson K, Caiazzo T, Yeung D, Parng C, Gorovits B.
    AAPS J; 2018 Nov 06; 21(1):4. PubMed ID: 30402825
    [Abstract] [Full Text] [Related]

  • 9. Drug Removal Strategies in Competitive Ligand Binding Neutralizing Antibody (NAb) Assays: Highly Drug-Tolerant Methods and Interpreting Immunogenicity Data.
    Partridge MA, Karayusuf EK, Shyu G, Georgaros C, Torri A, Sumner G.
    AAPS J; 2020 Aug 17; 22(5):112. PubMed ID: 32808205
    [Abstract] [Full Text] [Related]

  • 10. Indirect assessment of neutralizing anti-drug antibodies utilizing pharmacokinetic assay data.
    Vettermann C, Ortiz J, Lee S, Sanchez S, Victor HP, Ma M, Heath T, Gupta S.
    J Immunol Methods; 2016 Feb 17; 429():28-38. PubMed ID: 26711311
    [Abstract] [Full Text] [Related]

  • 11. Addressing Domain Specificity in the Development of a Cell-Based Binding Assay for the Detection of Neutralizing Antibodies Against a CD47xPD-L1 Bispecific Antibody.
    Luong M, Wang Y, Donnelly BB, Lepsy C.
    AAPS J; 2023 Sep 22; 25(6):91. PubMed ID: 37740131
    [Abstract] [Full Text] [Related]

  • 12. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A, Snoeck V, Bontinck L, Buyse MA, Pine SO.
    J Immunol Methods; 2020 Dec 22; 487():112896. PubMed ID: 33065122
    [Abstract] [Full Text] [Related]

  • 13. Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays.
    Xu W, Jiang H, Titsch C, Haulenbeek JR, Pillutla RC, Aubry AF, DeSilva BS, Arnold ME, Zeng J, Dodge RW.
    J Immunol Methods; 2015 Jan 22; 416():94-104. PubMed ID: 25445325
    [Abstract] [Full Text] [Related]

  • 14. Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2).
    Liao K, Sikkema D, Wang C, Lee TN.
    J Immunol Methods; 2013 Mar 29; 389(1-2):52-60. PubMed ID: 23298658
    [Abstract] [Full Text] [Related]

  • 15. Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics.
    Wu B, Chung S, Jiang XR, McNally J, Pedras-Vasconcelos J, Pillutla R, White JT, Xu Y, Gupta S.
    AAPS J; 2016 Nov 29; 18(6):1335-1350. PubMed ID: 27495119
    [Abstract] [Full Text] [Related]

  • 16. Development of a Cell-based Neutralizing Antibody Assay for Zinpentraxin Alfa: Challenges and Mitigation Strategies.
    Yin Z, Guerrero J, Melendez R, Andrews B, Peng K.
    AAPS J; 2023 Jul 20; 25(5):75. PubMed ID: 37468730
    [Abstract] [Full Text] [Related]

  • 17. Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment.
    Gouty D, Cai CC, Cai XY, Kasinath A, Kumar V, Alvandkouhi S, Yang J, Pederson S, Babbitt B, Peritt D, Rudy A, Koppenburg V, Dasilva A, Ullmann M, Liu S, Satterwhite C.
    AAPS J; 2017 Dec 28; 20(1):25. PubMed ID: 29285735
    [Abstract] [Full Text] [Related]

  • 18. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays.
    Kruzik A, Koppensteiner H, Fetahagic D, Hartlieb B, Dorn S, Romeder-Finger S, Coulibaly S, Weber A, Hoellriegl W, Horling FM, Scheiflinger F, Reipert BM, de la Rosa M.
    Hum Gene Ther Methods; 2019 Apr 28; 30(2):35-43. PubMed ID: 30734588
    [Abstract] [Full Text] [Related]

  • 19. Drug Target Interference in Immunogenicity Assays: Recommendations and Mitigation Strategies.
    Zhong ZD, Clements-Egan A, Gorovits B, Maia M, Sumner G, Theobald V, Wu Y, Rajadhyaksha M.
    AAPS J; 2017 Nov 28; 19(6):1564-1575. PubMed ID: 29063411
    [Abstract] [Full Text] [Related]

  • 20. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L, Squarzon L, Masiero S, Pacenti M, Marcati G, Mantelli B, Gabrielli L, Pascucci MG, Lazzarotto T, Caputo A, Palù G.
    Vaccine; 2014 Sep 15; 32(41):5357-62. PubMed ID: 25045814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.